Literature DB >> 14594131

Natural history of primary biliary cirrhosis.

Albert Parés1, Juan Rodés.   

Abstract

The natural history of PBC is characterized by slowly progressive cholestasis with liver damage, development of cirrhosis and its complications, and death, unless the patient undergoes liver transplantation. The disease has at least three clinical presentations, each with a different course and prognosis: the silent and usually less aggressive form, the asymptomatic form, and the symptomatic form. There are no identifiable features that distinguish the asymptomatic population who will remain symptom-free from those patients who will develop symptoms. As expected, the survival is longer in asymptomatic than in symptomatic patients. Overall survival of asymptomatic PBC is shorter than for an age- and gender-matched control population, but the patients remaining asymptomatic had a survival equal to that of the general population. Natural history studies have identified several variables associated with survival, particularly age, bilirubin, albumin, prothrombin time, ascites, encephalopathy, and advanced histological stage. Development of esophageal varices and hepatocellular carcinoma can also affect survival. Serum bilirubin level is, however, the most heavily weighted prognostic variable and can be used as a simplistic prognostic index for patients with PBC. In the last two decades, natural history models have been developed that include clinical, biochemical, and histological variables, the most popular being the Mayo model. It has the advantage ofavoiding histological variables, and therefore can be applicable to a broad spectrum of patients with PBC. The models may also be used to evaluate the efficacy of different new treatments. Prognostic models based on serial measurements of the independent predictors of poor prognosis would lead to a more accurate prediction of survival; however, they probably will not replace clinical outlook.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14594131     DOI: 10.1016/s1089-3261(03)00100-4

Source DB:  PubMed          Journal:  Clin Liver Dis        ISSN: 1089-3261            Impact factor:   6.126


  21 in total

Review 1.  Fatigue in primary biliary cirrhosis.

Authors:  Ghulam Abbas; Roberta A Jorgensen; Keith D Lindor
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2010-05-11       Impact factor: 46.802

Review 2.  Primary biliary cirrhosis: From bench to bedside.

Authors:  Elias Kouroumalis; George Notas
Journal:  World J Gastrointest Pharmacol Ther       Date:  2015-08-06

Review 3.  Primary biliary cirrhosis: Clinical and laboratory criteria for its diagnosis.

Authors:  Vasiliy Ivanovich Reshetnyak
Journal:  World J Gastroenterol       Date:  2015-07-07       Impact factor: 5.742

4.  Effects of total bilirubin on the prevalence of osteoporosis in postmenopausal women without potential liver disease.

Authors:  Lu-Qin Bian; Rong-Zhen Li; Zheng-Yun Zhang; Yan-Ji Jin; Hyung-Wook Kang; Zhen-Zhu Fang; Youn-Soo Park; Yoon-Ho Choi
Journal:  J Bone Miner Metab       Date:  2013-04-12       Impact factor: 2.626

5.  Risk factors and comorbidities in primary biliary cirrhosis: a controlled interview-based study of 1032 patients.

Authors:  M Eric Gershwin; Carlo Selmi; Howard J Worman; Ellen B Gold; Mitchell Watnik; Jessica Utts; Keith D Lindor; Marshall M Kaplan; John M Vierling
Journal:  Hepatology       Date:  2005-11       Impact factor: 17.425

Review 6.  Primary biliary cirrhosis and liver transplantation.

Authors:  Nobuhisa Akamatsu; Yasuhiko Sugawara
Journal:  Intractable Rare Dis Res       Date:  2012-05

Review 7.  Concept on the pathogenesis and treatment of primary biliary cirrhosis.

Authors:  Vasiliy-Ivanovich Reshetnyak
Journal:  World J Gastroenterol       Date:  2006-12-07       Impact factor: 5.742

Review 8.  Options for treatment of primary biliary cirrhosis.

Authors:  Ye H Oo; James Neuberger
Journal:  Drugs       Date:  2004       Impact factor: 9.546

Review 9.  Advances in antifibrotic therapy.

Authors:  Zahra Ghiassi-Nejad; Scott L Friedman
Journal:  Expert Rev Gastroenterol Hepatol       Date:  2008-12       Impact factor: 3.869

Review 10.  Primary biliary cirrhosis.

Authors:  Simon Hohenester; Ronald P J Oude-Elferink; Ulrich Beuers
Journal:  Semin Immunopathol       Date:  2009-07-15       Impact factor: 9.623

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.